A regimen to minimize pain during blue light photodynamic therapy of actinic keratoses: Bilaterally controlled, randomized trial of simultaneous versus conventional illumination - 13/03/20
Abstract |
Background |
Blue light photodynamic therapy (PDT) is effective for actinic keratosis, but many patients experience stinging pain during illumination.
Objective |
To compare a conventional regimen (1 hour of 5-aminolevulinic acid [ALA] preincubation, followed by blue light) versus a new modified regimen in which blue light is started immediately after ALA application.
Methods |
A clinical trial with a bilaterally controlled, intrapatient study design was conducted with 23 patients. Topical 20% ALA was applied to the entire face and/or scalp. On 1 side of the body, blue light was started immediately and continued for either 30, 45, or 60 minutes (simultaneous PDT). On the contralateral side, the blue light began 1 hour after ALA application and lasted 1000 seconds (conventional PDT). Pain was evaluated on a scale from 0 to 10. Actinic keratosis lesion counts were determined by clinical examination and photography.
Results |
All patients experienced significantly less pain during simultaneous illumination than during the conventional regimen. At 3 months after treatment, lesion clearance was nearly identical on the 2 sides, as determined by statistical testing of noninferiority ± 15% margin.
Limitations |
Although bilaterally controlled, the study was relatively small. Additional studies are recommended.
Conclusion |
The modified PDT regimen is essentially painless, yet it provides treatment efficacy similar to a conventional regimen.
Le texte complet de cet article est disponible en PDF.Key words : clinical research, oncology, phototherapy, skin cancer, therapeutics
Abbreviations used : AK, ALA, PDT, PpIX
Plan
| Funding sources: Supported by the Cleveland Clinic Research Protocol Committee fund (to Dr Maytin), Sun/DUSA Pharmaceuticals, investigator-initiated grant (to Dr Maytin), and grant number P01CA084203 (Drs Hasan and Maytin) from the National Cancer Institute of the National Institutes of Health, USA. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Reviewed and approved by Cleveland Clinic institutional review board (approval no. 14-374). |
|
| Reprints not available from the authors. |
Vol 82 - N° 4
P. 862-868 - avril 2020 Retour au numéro
Article précédent
- BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
- Omar Hasan Ali, David Bomze, Sandra S. Ring, Fiamma Berner, Mirjam Fässler, Stefan Diem, Marie-Therese Abdou, Christoph Hammers, Shirin Emtenani, Anne Braun, Antonio Cozzio, Bernhard Mani, Wolfram Jochum, Enno Schmidt, Detlef Zillikens, Christian D. Sadik, Lukas Flatz
- Greater efficacy of SPF 100+ sunscreen compared with SPF 50+ in sunburn prevention during 5 consecutive days of sunlight exposure: A randomized, double-blind clinical trial
- Indermeet Kohli, Cynthia L. Nicholson, Joshua D. Williams, Alexis B. Lyons, InSeok Seo, Prithwiraj Maitra, Xiaoyan Tian, Evren Atillasoy, Henry W. Lim, Iltefat H. Hamzavi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?